Dimerix Limited · ASX:DXB
Dimerix — Shareholder Meeting (October 2017)
15 slides from Dimerix's shareholder meeting presentation, Oct 19, 2017
Slide 1: CEO Presentation Dimerix 2017 AGM
For personal use only CEO Presentation Dimerix 2017 AGM 1
Slide 2: Company strategy
Company strategy Dimerix Limited (ASX:DXB) For personal use only 1. Using proprietary “Receptor HIT” drug discovery platform to identify multiple development programs 2. Lead program is DMX-200 in Phase 2 human trials for Chronic Kidney Disease (CKD) • Uses compounds that are already known 3. Positi
Slide 3: Corporate overview
Corporate overview For personal use only Corporate Snapshot ASX Code DXB Share Price (18 Oct 17) $.009 Share price history Market cap $16.5m Cash (30 Jun 2017) $2.2m 0.015 (R&D tax incentive, $545,771 received 17th October 2017) Shares on issue* 1,829.9m (Post consolidation 91.9m) 0.01 Major Shareho
Slide 4: 2017 has been an instrumental year in Dimerix's history
2017 has been an instrumental year in Dimerix’s history For personal use only Aug-16 Oct-16 Nov-16 Dec-16 Jan-17 June-17 July-17 US Federal Drug - Interim data for - CEO Kathy Harrison - Formal recruitment - Raised $2m for - Meeting with 7 US Headline DMX-200 Administration (FDA) DMX-200 Phase 2a ap
Slide 5: Chronic kidney disease (CKD) - market opportunity
Chronic kidney disease (CKD) - market opportunity For personal use only • CKD is a global health problem affecting over 10% of the population with 26 million patients in the US alone • Growing in incidence due to large number of people living with obesity and diabetes • CKD gets progressively worse,
Slide 6: Current treatments for CKD
Current treatments for CKD For personal use only • Damaged kidneys “leak” proteins into the urine. This is called proteinuria and is the most common symptom of kidney disease – relevant measure of treatment efficacy (a prognostic indicator of future kidney damage) • First line therapy is reducing bl
Slide 7: Tight competitive landscape
Tight competitive landscape For personal use only • NASDAQ: RTRX • NASDAQ: CCXI • Market cap : ~US$ 915 million • Market Cap: ~US$ 380 million • Phase 2 asset, sparsentan, for treating • Completed Phase 2 for CCX140 in FSGS – a dual angiotensin endothelin diabetic nephropathy – a CCR2 receptor block
Slide 8: DMX-200 – Dimerix lead program for CKD
DMX-200 – Dimerix lead program for CKD For personal use only • DMX-200 is a tablet which is taken in conjunction with existing medications • DMX-200 is being developed as an ‘adjunct’ therapy, avoiding complications of combination therapy development • Patients continue taking their standard of care
Slide 9: DMX-200 phase 2a trial outcomes
DMX-200 phase 2a trial outcomes For personal use only End points met ü Primary end point met – no serious safety or tolerability concerns observed when DMX- 200 used as an adjunct to standard of care drug, “irbesartan“ ü Secondary end point – showed encouraging efficacy ü 6 of 24 patients achieved >
Slide 10: DMX-200 phase 2a trial outcomes
DMX-200 phase 2a trial outcomes For personal use only Treatment effectiveness: proteinuria level reduction Post-hoc: • 11 of 24 patients completing the DMX-200 Trial study requested and were granted 100% Irbesartan: 24 – 38% reduction* access to continue using DMX-200, (current standard of care) und
Slide 11: About the ASN meeting
About the ASN meeting For personal use only • The world’s premier nephrology meeting, attended by more than 13,000 kidney professionals • Used as a platform for discussing innovation in drug development with clinicians and potential partners • Dimerix’s abstract was accepted enabling presentation of
Slide 12: Medical advisory board
Medical advisory board For personal use only David Packham – Chair David Power • Director of the Melbourne Renal Research Group. • Director of Nephrology at Austin Health and Professorial • More than 30-years experience participating in over Associate at the University of Melbourne. 40 international
Slide 13: DMX-200 – Phase 2b Design and Pipeline
DMX-200 – Phase 2b Design and Pipeline • Double blind placebo controlled For personal use only Development • Dosing period 6 months (3 Path by CKD Pre clinical Observational Phase 1 Phase 2a Phase 2b Phase 3 months run in and 3 months sub-group follow up to mitigate individual Orphan path/ patient v
Slide 14: Significant next steps
Significant next steps For personal use only ü Human pharmacokinetics (PK) study to optimise dose of DMX-200 for extended release formulation on track to complete 2H CY2017 (3 tablets daily reduced down to 2 tablets daily) ü NEW detailed Phase 2a data to be released on 2nd November 2017 in the Annua
Slide 15: Contact
For personal use only Contact Kathy Harrison Chief Executive Officer +61 419 359 149 kathy.harrison@dimerix.com Dimerix Limited ACN 001 285 230 www.dimerix.com